Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer
Latest Information Update: 15 Oct 2021
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary) ; Pyrotinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Carcinoma; Ductal carcinoma
- Focus Therapeutic Use
- Acronyms NeoTPPF
- 15 Oct 2021 New trial record